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Abstract 
The role of protein kinases in maintaining basal expression of voltage-gated K + channel mRNA was examined in GH 3 clonal pituitary 
cells. Nonspecific inhibition of protein kinases with H7 or staurosporine markedly decreases Kvl.5 K + channel gene transcription and 
mRNA without producing asubstantial change in Kvl.4 mRNA. Selective inhibitors for protein kinase C, Ca2+-calmodulin ki ases, and 
tyrosine kinases do not affect Kvl.5 mRNA expression. In contrast, he Rp-diastereomer of adenosine 3',5'-cyclic monophosphorothioate, 
a specific inhibitor of protein kinase A, partially inhibits Kvl.5 mRNA expression (~ 40%), and this effect was antagonized by 
8-bromo-adenosine 3',5'-cyclic monophosphate. Thus, protein kinase A and at least one other kinase are required for basal Kvl.5 mRNA 
expression i  pituitary cells. 
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I. Introduction 
Multiple voltage-gated K ÷ channels are essential for 
determining the diverse shapes and frequencies of action 
potentials in excitable cells. Molecular biological studies 
have identified a large number of mammalian genes that 
encode voltage-gated K ÷ channels [1-3]. These channels 
vary in their activation, inactivation, single channel con- 
ductance, and other structural characteristics which may be 
important for modulation by phosphorylation and interac- 
tion with G-proteins [1-4]. The diversity of K ÷ channel 
genes may also be beneficial for tissue- and cell type- 
specific expression. Although most of the known genes are 
expressed in the brain, expression of these genes varies in 
different issues, regions of the brain, and cell types [4]. In 
addition to tissue- and cell type-specific expression, K ÷ 
channel gene expression may be differentially regulated by 
extracellular signals, such as hormones and neurotrans- 
Abbreviations: PKA, protein kinase A; PKC, protein kinase C; PKG, 
protein kinase G; Rp-cAMP[S], Rp-diastereomer of adenosine 3',5'- 
monophosphorothioate; Br-cAMP, 8-bromo-adenosine 3',5'-cyclic 
monophosphate; CPT-cAMP, 8-(4-chlorophenylthio)-adenosine 3',5'- 
cyclic monophosphate; TPA, 12-O-tetradecanoylphorbol 13-acetate. 
* Corresponding author. E-mail: Levitan@BNS.pitt.edu. Fax: + 1 (412) 
6481945. 
0167-4889/95/$09.50 © 1995 Elsevier Science B.V. All rights reserved 
SSDI 0167-4889(94)00205-3 
mitters. Indeed, we have previously shown that glucocorti- 
coid hormones pecifically increase pituitary Kvl.5 ex- 
pression in vitro and in vivo [5-7]. Thus, the diversity of 
K ÷ channels may allow for complex regulation of ex- 
citability at the level of gene expression. 
Protein kinases play an essential role in controlling 
excitability. First, it is established that many neurotrans- 
mitters and hormones modulate the gating of K ÷ channels 
already present in plasma membrane. In some cases, these 
extracellular signals affect channel gating by changing the 
phosphorylation state of channel proteins [8,9]. Protein 
kinases may also be involved in long-term regulation of 
excitability by influencing K ÷ channel gene expression. 
Tissue- and cell type-specific expression of genes is deter- 
mined and maintained by specific sets of transcription 
factors that directly or indirectly interact with regulatory 
regions of target genes [10,11]. The activity of some of 
these transcription factors can be regulated by protein 
kinases and/or phosphatases [12]. Thus, protein kinases 
may play an important role in maintaining and regulating 
expression of K + channel genes. 
To test this possibility, we examined involvement of 
protein kinases in voltage-gated K + channel gene expres- 
sion in GH 3 clonal pituitary cells. PCR analysis indicates 
that these cells express at least four K ÷ channel genes: 
Kvl.4, Kvl.5, Kv2.1, and a homolog of a mouse shal 
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gene [13]. We have detected significant amounts of tran- 
scripts and proteins for KvlA. and Kvl.5, the two Shaker- 
related genes [5-7]. In this report, we examine the ability 
of various protein kinase inhibitors to affect basal expres- 
sion of the two Shaker-related genes. We show that pro- 
tein kinase A and at least one other protein kinase are 
required for maintaining basal expression of Kvl.5 (but 
not Kvl.4) K ÷ channel mRNA. 
fetal calf serum. For treatment of the cells, chemicals were 
dissolved in either dimethyl sulfoxide or water and added 
to the culture medium at a final solvent concentration of 
less than 0.1%. This concentration of the solvents showed 
no significant effect on Kvl.5 mRNA level and gene 
transcription. 
2.3. RNA blot hybridization 
2. Mater ia l s  and  methods  
2.1. Materials 
H7 was purchased from Seikagaku (Tokyo, Japan) and 
LC Laboratories (Woburn, MA). Staurosporine, laven- 
dustin A, and calmidazolium were from Calbiochem (San 
Diego, CA). Chelerythrine, Iso-H7, and HA1004 were 
from LC Laboratories. Rp-diastereomer of adenosine 
Y,5'-cyclic monophosphorothioate (Rp-cAMP[S]) was 
from RBI (Natick, MA). Genistein was from Gibco-BRL 
(Gaithersburg, MD), An active form of phorbol ester, 
12-O-tetradecanoylphorbol 13-acetate (TPA), 8-bromo- 
adenosine 3',5'-cyclic monop]hosphate (Br-cAMP), and 8- 
(4-chlorophenylthio)-adenosine Y,5'-cyclic monophosphate 
(CPT-cAMP) were from Sigma (St. Louis, MO). 
2.2. Cell culture 
GH 3 cells were purchased from American Type Culture 
Collection (Rockville, MD) and cultured in Ham's F-10 
medium supplemented with 15% horse serum and 2.5% 
Total RNA was isolated by acid phenol guanidium 
thiocyanate extraction [14]. Kvl.4 and Kvl.5 mRNAs were 
detected by Northern blot hybridization using random 
prime-labelled XbaI-Bgll I  fragment of rat Kvl.4 cDNA 
corresponding to nucleotides 27-2167 [15] and EcoRI- 
HindlII fragment of rat Kvl.5 cDNA corresponding to 
nucleotides 1123-2136 [16], respectively, as described 
previously [6,7]. The channel mRNA levels were measured 
by densitometry and normalized using intensity of ethid- 
ium bromide staining of 28S ribosomal RNA [17]. 
2.4. Nuclear transcription assay 
Nuclei were prepared from GH 3 cells grown on two 
100 mm dishes, and transcription reaction was performed 
with 50 /xCi [32p]UTP (approx. 3000 Ci/mmol),  as de- 
scribed previously [6]. After reaction, 32 P-labelled RNAs 
were isolated by acid phenol guanidium thiocyanate x- 
traction [18]. Incorporation of radioactivity into RNA was 
determined by measuring trichloroacetic acid-precipitable 
radioactivity. Approximately 3 .10  6 cpm radioactivity of 
32 P-labelled RNAs was hybridized with a nylon filter that 
was previouslylinked to linearized plasmid DNAs. Rat 
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Fig. 1. Effect of H7 on Kvl.4 and Kvl.5 mRNA levels. (A) Each lane represents 5 p,g of total RNA isolated from GH 3 cells treated with 20 /zM H7 for 
various times. Top: Kvl.5 probe detects 3.5 kb band that is down-regulated by the kinase inhibitor. Bottom: Kvl.4 probe reacts with various izes of 
mRNAs from GH 3 cells. Major bands on the blot are approximately 12 kb, 11 kb, and 6 kb in sizes. (B) The three major bands on Kvl.4 blots and 3.5 kb 
Kvl.5 mRNA were measured by densitometry and normalized with intensity of ethidium bromide staining of 28S ribosomal RNA. Open and closed circles 
represent relative amounts of 6 kb Kvl.4 mRNA and 3.5 kb Kvl.5 mRNA, respectively. The other two Kvl.4 mRNAs (12 and 11 kb) changed similarly to 
the 6 kb Kvl.4 mRNA in all experiments. Each point represents the mean of two independent experiments. Deviations did not exceed 20% of the mean. 
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fl-actin and Kvl.5 cDNAs were subcloned into pGEM1, A 
and the plasmids were linearized with unique restriction H7 Iso-H7 HA1004 
sites in the polylinker egion [6]. 0 5 10 20 0 5 10 20 0 5 10 20 (~tM) 
3. Results 
To examine if protein kinases are required for basal 
expression of K + channel genes, we first tested if the wide 
spectrum protein kinase inhibitor H7 might affect steady 
state levels of Kvl.4 and Kvl.5 mRNAs in GH 3 cells (Fig. 
1). H7 (20 /zM) rapidly and dramatically decreased Kvl.5 
mRNA expression so that it was nearly undetectable after 
4 h of treatment. In contrast, only a slight decrease in 
Kvl.4 mRNA was seen. Similar effects on Kvl.5 and 
Kvl.4 channel mRNAs were also obtained with 1 /xM 
staurosporine, another nonspecific protein kinase inhibitor 
(n = 3 for 4 h of treatment, Fig. 4). Thus, protein kinase 
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Fig. 2. Inhibition of Kvl.5 gene transcription by H7 or staurosporine. (A) 
GH 3 cells were untreated (None) or treated with 20 pM H7 or 1 /~M 
stanrospodne for 1 h. In vitro transcription assay was performed with 
approx. 5-106 nuclei. Approximately 3-106 cpm 32p-labelled RNA was 
used for hybridization. The filter for hybridization was linked to lin- 
earized plasmid DNAs; fl-actin eDNA (Actin), Kvl.5 eDNA (Kvl.5), 
and vector alone (pGEM). After washing, the membrane was exposed to 
an X-ray film with an intensifying screen at -80°C for 3 days. (B) 
Transcription activity was measured by densitometry. Kvl.5 transcription 
is expressed as percentages of ~-actin transcription i the same blot. Bars 
represent the means of two independent experiments. Deviations did not 
exceed 25% of the mean. 
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Fig. 3. Specific inhibition of Kvl.5 mRNA expression by H7. (A) GH 3 
cells were treated with indicated concentrations of H7 of its analogs for 3 
h. Each lane represents 5 p~g of total RNA. Top: Northern blot with 
Kvl.5 eDNA probe. Bottom: ethidium bromide staining of ribosomal 
RNAs. (B) Each point represents he mean of two independent experi- 
ments. Deviations did not exceed 15% of the mean. Closed circles, H7; 
open circles, Iso-H7; open triangles, HA1004. 
activity is specifically required for basal expression of 
Kvl.5 mRNA in GH 3 cells. 
Since Kvl.5 mRNA turns over rapidly with a half-life 
of approx. 35 min in GH 3 cells [6], inhibition of the gene 
transcription could solely account for this rapid decrease in 
Kvl.5 mRNA. Therefore, the effect of the kinase inhibitors 
on Kvl.5 gene transcription was directly examined with 
nuclear run-on assays (Fig. 2). Treatment with either 20 
/zM H7 or 1 /xM staurosporine for 1 h markedly inhibited 
Kvl.5 gene transcription. Thus, the rapid down-regulation 
of Kvl.5 mRNA by the kinase inhibitors is at least in part 
due to inhibition of the channel gene transcription. 
H7 inhibits many protein kinases, including PKC, PKA, 
and PKG, with K i values of < 10 /xM [19,20]. It is 
known that two H7 analogs, Iso-H7 and HA1004, are 
equally effective at inhibiting the latter two kinases, but 
require ~ 10-times higher concentrations to inhibit PKC 
[19,20]. Thus, if only PKA and/or PKG were required for 
maintaining basal expression of Kvl.5 mRNA, then the 
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two H7 analogs would be equaUy effective at reducing the 
level of channel mRNA. However, while application of 20 
/xM H7 completely down-regulated Kvl.5 mRNA, equiva- 
lent doses of Iso-H7 or HA1004 decreased Kvl.5 mRNA 
by only 30-40% (Fig. 3). This result could occur if a 
single kinase that is relatively insensitive to the H7 analogs 
was required for basal expression of Kvl.5 mRNA. Alter- 
natively, this result might arise if multiple kinases that 
differ in their sensitivity to H7 and its analogs are required 
for basal expression of the channel mRNA. 
To differentiate between these possibilities, we used 
more specific protein kinase inhibitors: chelerythrine, a 
selective inhibitor of protein kinase C [21]; Rp-cAMP[S], a 
specific inhibitor of PKA [212]; and genistein and laven- 
dustin A, inhibitors of tyrosine kinases [23,24] were tested. 
In addition, calmidazolium, a calmodulin antagonist, was 
employed in order to inhibit Ca2+-calmodulin kinases [25]. 
Treatment with 20 /xM chelerythrine, which is known to 
inhibit PKC with an IC50 of < 100 nM [21], did not 
significantly affect Kvl.5 mRNA level (Fig. 4). Further- 
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Fig. 4. Effect of various protein kinase inhibitors on Kvl.5 mRNA 
expression. (A) Each lane represents 5 ~g total RNA isolated from GH 3 
cells treated with one of the inhibit:ors for 4 h. Top: Northern blot with 
Kvl.5 cDNA probe. Lanes: 1, none; 2, 20 /.~M H7; 3, 1 ~M stau- 
rosporine; 4, 20 ~M chelerythrine; 5, 0.2 raM Rp-eAMP[S]; 6, 100 ~M 
genistein; 7, 10 bLM lavendustin A; 8, 5 /xM calmidazolium. Bottom: 
cthidium bromide staining of ribosomal RNAs. (B) Columns and error 
bars represent he means and S.D., respectively (n= 3). * and * * 
indicate P < 0.05 and P < 0.01 compared to control, respectively (two- 
tailed t-test). 
more, down-regulation f PKC by pretreating the cells for 
24 h with 1 /xM TPA [26] did not influence Kvl.5 mRNA 
(data not shown). Likewise, the tyrosine kinase inhibitors 
and the calmodulin antagonist at concentrations of 50- 
100-times higher than the reported g i values [23-25] 
failed to produce significant changes in the channel mRNA 
level (Fig. 4). Thus, PKC, Ca2+-calmodulin kinase, and 
tyrosine kinases that are sensitive to genistein or laven- 
dustin A are not required for basal expression of Kvl.5 
mRNA. 
In contrast, reatment with 0.2 mM Rp-cAMP[S] signif- 
icantly decreased Kvl.5 mRNA by approx. 30% (Figs. 4 
and 5). The failure of Rp-cAMP[S] to completely inhibit 
channel mRNA expression was not due to use of an 
insufficient dose. First, it has been shown that application 
of Rp-cAMP[S] to culture cells produces maximal effects 
at concentrations of < 0.1 mM [22]. Furthermore, we 
found that a higher concentration of Rp-cAMP[S] (0.5 
mM) produced only a slightly larger decrease in Kvl.5 
mRNA than 0.2 mM Rp-cAMP[S] (Fig. 5A and B). If the 
effect of Rp-cAMP[S] was mediated by its PKA inhibition, 
then the cAMP agonist Br-cAMP, because of its much 
higher affinity for the regulatory subunit of PKA, should 
competitively antagonize the action of Rp-cAMP[S]. As 
previously reported [5], application of either 1 mM Br- 
cAMP (Fig. 5C and D) or 0.5 mM CPT-cAMP (data not 
shown) does not affect basal Kvl.5 mRNA level in GH 3 
cells. However, 1 mM Br-cAMP completely antagonized 
the effect of 0.5 mM Rp-cAMP[S] (Fig. 5C and D). Thus, 
while increasing PKA activity does not alter Kvl.5 mRNA 
expression, inhibiting the kinase activity partially down- 
regulates expression of the channel mRNA. Taken to- 
gether, our results with a variety of kinase inhibitors 
indicate that PKA and at least one unidentified H7- 
staurosporine-sensitive kinase are required for basal ex- 
pression of Kvl.5 K ÷ channel mRNA in GH 3 clonal 
pituitary cells. 
4. Discussion 
Excitable cells vary in the pattern of electrical activity 
they spontaneously produce. For example, while skeletal 
muscle remains hyperpolarized in the absence of input, 
many other cells (e.g. some neurons, pituitary cells, and 
cardiac myocytes) are capable of producing spontaneous 
rhythmic beating or bursting action potential activity. The 
cloning of a wide variety of voltage-gated ion channels 
suggests that this diversity may be determined and main- 
tained by controlling the assortment of channel genes 
expressed by each cell type. In this study, we demonstrated 
that basal protein kinase activity is required for maintain- 
ing Kvl.5 (but not Kvl.4) channel mRNA expression in 
GH 3 clonal pituitary cells. Thus, the expression of the 
Kvl.5 K ÷ channel gene is not simply constitutive, but 
actively maintained by protein kinases. 
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Recent studies have shown that the expression of volt- 
age-gated K ÷ channel gene expression is not static [6-  
8,27-29]. Rather it is regulated by hormones [5-7,27], 
seizure activity [28], drugs [29], and second messengers 
[30,31]. Our results further support the proposal that ex- 
citability may be altered in response to extracellular sig- 
nals by altering the expression of voltage-gated K ÷ chan- 
nels. Indeed, many of the reported effects may have in- 
volved changes in protein kinase and/or  phosphatase ac- 
tivities. 
Mori et al. [30] recently reported that cAMP regulates 
Kvl .5 gene transcription i  a cell-specific manner: cAMP 
up-regulates the channel gene transcription in neonatal 
atrial cardiomyocytes and C2C12 cells differentiated into 
myotubes, whereas it down-regulates Kvl .5 mRNA and 
gene transcription i  GH 3 cells. However, our results with 
Rp-cAMP[S] and Br-cAMP demonstrate that increasing 
cAMP does not affect the steady state level of Kvl .5 
mRNA in GH 3 cells. Rather inhibition of PKA signifi- 
cantly decreases Kvl .5 mRNA expression. This discrep- 
ancy might be due to different culture and treatment 
conditions used by the two groups: Mori et al. [30] treated 
cells with both Br-cAMP and the phosphodiesterase in-
hibitor isobutylmethylxanthine in serum-free medium. 
However, we could not reproduce the reported results 
under several different conditions including cotreatment 
with the cAMP analog and phosphodiesterase inhibitor and 
varying times of culture in the absence of serum before 
treatment. Hence, our results suggest hat increasing cAMP 
concentration has no significant effect on Kvl .5 mRNA 
expression and that steady-state concentration of cAMP is 
sufficient to maintain basal Kvl .5 mRNA expression in 
clonal pituitary cells. 
Our results suggest hat at least two protein kinases are 
essential for maintaining basal Kvl .5 mRNA expression in 
GH 3 cells. One (or more) of these is unidentified and 
sensitive to H7 and staurosporine. The results with the H7 
analogs, Iso-H7 and HA1004, suggested that the dramatic 
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Fig. 5. Involvement ofprotein kinase A in Kvl.5 mRNA expression. (A) Each lane represents 5 /xg total RNA isolated from cells treated with indicated 
concentrations of Rp-cAMP[S] for 4 h. Top: Northern blot with Kvl.5 cDNA probe. Bottom: ethidium bromide staining of ribosomal RNAs. (B) Points 
and error bars represent the means and S.D., respectively (n= 3). * indicates P < 0.05 compared to control (two-tailed t-test). (C) GH 3 cells were 
untreated (1) or treated with 1 mM 8-bromo cAMP (2), 0.5 mM Rp-cAMP[S] (3), or both chemicals (4) for 4 h. Each lane represents 5 /.~g total RNA. 
Top: Northern blot with Kvl.5 cDNA p~'obe. Bottom: ethidium bromide staining of ribosomal RNAs. (D) Kvl.5 mRNA levels in (C) were compared to 
control. Columns and error bars represent the means and S.D., respectively (n= 3). * Kvl.5 mRNA level in cells treated with 0.5 mM Rp-cAMP[S] was 
significantly ower than that in cells treated with 1 mM Br-cAMP or both chemicals (two-tailed t-test, P < 0.05). 
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decrease in Kvl .5 mRNA by H7 or staurosporine might be 
at least partially due to its specific inhibition of PKC. 
However, the selective PKC inhibitor chelerythrine did not 
affect the channel mRNA. Furthermore, treatment of the 
cells for 24 h with 1 /xM TPA, which is known to 
down-regulate about 95% of PKC activity in GH4C 1 cells, 
a subclone of GH 3 cells [26], produced no significant 
change in Kvl .5 mRNA. Finally, since H7 and stau- 
rosporine inhibit both PKA and PKC, it was possible that 
inhibition of PKC alone might not produce any effect on 
Kvl.5 mRNA expression. Rather, inhibition of PKC might 
potentiate the effect produced by inhibition of PKA. How- 
ever, we found that co-treatment with 20/xM HA1004 and 
20 /xM chelerythrine for 4 h produced no additional 
decrease in the channel mRNA compared to HA1004 
alone (data not shown). Therefore, PKC is unlikely to 
simply mediate or to influence in cooperation with PKA 
basal Kvl .5 mRNA expression in clonal pituitary cells. 
A recent study with neonatal cardiac myocytes [31] 
suggested that protein kinases are involved in Kvl .4 mRNA 
expression: the PKC activator TPA increases the steady- 
state level of Kvl .4 mRNA in these cells [31]. However, in 
the present study we demonstrated that H7 or stau- 
rosporine did not cause a substantial change in the basal 
level of Kvl .4 mRNA. Furthermore, we found that treat- 
ment of GH 3 cells with 100 nM TPA for 4 h did not affect 
steady state level of Kvl .4 mRNA (unpublished observa- 
tion). Thus, PKC does not maintain or induce Kvl .4 
mRNA expression in GH 3 cells. The inability of PKC to 
influence Kvl .4 mRNA level may be due to differences in 
signal transduction mechanisms operating on the channel 
mRNA expression in the two cell types. 
Most of the effect of the wide spectrum kinase in- 
hibitors appeared to be due to reduction of channel gene 
transcription. However, because the H,7- and stau- 
rosporine-induced down-regulation of Kvl .5 mRNA was 
even more dramatic than the', measured inhibition of tran- 
scription, the kinase inhibitors might also affect Kvl .5 
mRNA stability. We attemplLed to determine if PKA also 
acts transcriptionally. However, because of variability in 
the nuclear run-on assay, we were unable to detect a 
significant change in the transcription of Kvl .5 gene by 
Rp-cAMP[S]. Thus, it is certainly possible that effect of 
Rp-cAMP[S] on Kvl .5 mRNA expression might be due to 
destabilization of the message. More sensitive methods for 
measuring transcription, such as a reporter gene assay, or 
direct measurement of mRNA turnover may be needed to 
resolve this issue. 
Protein kinases acutely modulate and/or  maintain the 
activity of voltage-gated ion channels in plasma membrane 
[8,9]. An earlier study on voltage-gated Ca 2÷ channels has 
shown that phosphorylation by PKA is necessary for the 
voltage-dependent opening of L-type (but not T-type) Ca 2 ÷ 
channels in GH 3 cells [32]. In this study, we found that 
protein kinase activity is essential for Kvl .5 (but not 
Kvl .4) K ÷ channel gene expression in GH 3 cells. There- 
fore, protein kinase activity is specifically required for 
maintaining the activity and/or  expression of some ion 
channels. Furthermore, in some cases multiple kinases are 
involved in the acute modulation of voltage-gated K + 
currents. For example, in Jurkat T cells, PKA-induced 
inhibition of the n-type K ÷ current, presumably carded by 
Kvl.3 K ÷ channels, requires the presence of PKC [33]. 
Although we could not identify all of the protein kinases 
necessary for maintaining basal Kvl .5 mRNA expression, 
at least two protein kinases appear to be involved. Thus, 
protein phosphorylation by multiple kinases plays an es- 
sential role in both acute modulation and long-term control 
of expression of K ÷ channels. 
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